Shares in Arcutis Biotherapeutics (NASDAQ: ARQT) soared by almost 30% in trading to 10:30 a.m. ET today. The move comes after ...
Experts discuss the impact of severe eczema on children’s daily lives and the role of newer non-steroidal topical therapies ...
Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to ...
Skin conditions with Parkinson’s disease are common and manageable. By paying attention to these symptoms, patients can ...
New clinical data demonstrate Zoryve's effectiveness in treating atopic dermatitis, reducing sleep disruptions and maintaining disease control with minimal adverse events across all ages.
Arcutis Biotherapeutics has recently seen its consensus analyst price target hold steady at $23.38, even as expectations around its risk profile and growth have shifted slightly. This stability comes ...
INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...
The use of dupilumab for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents. The association between dupilumab and psoriasis was ...
In the Mediterranean diet group, 47.4% achieved a 75% reduction in PASI compared with 0% in the control group. HealthDay News — A 16-week Mediterranean diet intervention significantly improves ...
Major advancements in psoriasis treatments in the past two decades have given people living with the autoimmune condition a wide range of options for controlling symptoms. There are more than a dozen ...
Sept 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's (BMY.N), opens new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback